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Despite the technical advances in radiotherapy, toxicity to healthy tissues remains the limiting factor of treatment. The aim of this work is to
highlight one or more blood markers whose ex vivo variations after irradiation (IR) could predict the occurrence of late cutaneous side
effects. For this preliminary study, we selected patients with Merkel cell carcinoma (MCC) because, although rare, their treatment only
includes radiotherapy and the dosimetry data are accurate to the skin. Two groups of patients were established according to the grade of
late cutaneous toxicity after adjuvant IR for MCC: (i) no or little toxicity (grade 0, 1 or 2 of the RTOG), (ii) marked toxicity (grade 3 or 4 of the
RTOG). In order to try to discriminate these 2 groups, markers of interest were selected and measured on the different compartments of ex
vivo irradiated blood. At the lymphocyte level, cell cycle and apoptosis (flow cytometry) and genotoxicity (micronuclei) were quantified.
Oxidative stress was evaluated by the determination of the erythrocyte activity of the main antioxidant enzymes (SOD, CAT, GPx) as well as
the generated degradation products (carbonyls and LPO in erythrocytes, secretion of 8-oxodG in plasma). The inflammatory phenomena
were measured in the plasma by flow cytometry using LEGENDplex kits: IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-
12p70, IL-17A, IL-18, IL-23, and IL-33. Since February 2017, 18 patients treated for a MCC at Cancer Center François Baclesse (Caen, France)
were included in the study. Trends, but also some significant differences in blood markers tested after ex vivo irradiation were observed, most
often after a dose of 10 Gy. The originality of this preliminary study is based on the pool of markers used on a homogeneous population of
patients. The results will then be confirmed in a prospective framework.
Materials and Methods
Two groups of patients (n=10)
were constituted among the
patients treated by radiotherapy
for a MCC (Merkel Cell Carcinoma)
at the Cancer Centre François
Baclesse (Caen, France). One of
these groups presented extensive
skin lesions (≥ grade 3 RTOG)
called « Tox ≥ 3 ». The other group
presented no or few skin side
effects, it was called « Tox ≤ 2 ».
MCC is a rare pathology but was
chosen because its treatment is
only radiotherapy (no hormone
therapy, no chemotherapy) and
dosimetry to the skin is well
defined in technical records. For
the protocol, see Figure 1.
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Figure 1. Experimental protocol of PAESCART study.
Results
Eighteen patients were included since
February 2017: 9 in the group « Tox ≥ 3 »
(mean age = 74.4 years) and 9 in the group
« Tox ≤ 2 » (mean age = 73.7 years). No
significant differences were observed
between patients in terms of age, received
irradiation dose etc. At 2 Gy, there is a
decrease in lymphocyte apoptosis (sub-G1
peak) in the group of patients « Tox ≥ 3 »
compared to the group « Tox ≤ 2 » (Fig. 2).
Micronucleus frequency is also decreased in
the same manner but at the irradiation dose
of 10 Gy (Fig. 3). At 10 Gy, there is also a
decrease in SOD activity in the group « Tox ≥
3 » (Fig. 4). In th same way, a decrease was
observed in the level of reduced and oxidized
glutathione (Fig. 5). There is no significant
decrease but only a trend concerning IL-8
(Fig. 6) and other inflammatory cytokines, as
well as degradation products as carbonyls,
lipid peroxides (data not shown).
Figure 2. Lymphocyte apoptosis in both groups of 
patients.
Figure 3.  Micronucleus frequency per 1000 binucleated
lymphocytes in both groups of patients. 
Conclusions
On the 18 patients recruited for this study, differences were observed in
blood biomarkers after ex vivo irradiation. Patients the most
radiosensitive seemed to present a decrease in defense mechanisms
resulting in a decrease in ROS detoxification. Decrease in superoxide
dismutase activity could lead to a lower production of hydrogen peroxide
which could generate less DNA damage and apoptosis.
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Figure 4.  Superoxide dismutase activity in erythrocytes in 
both groups of patients. Mean value in unirradiated samples is
6.8 UI/mg of proteins.
Figure 5.  Reduced (left) and oxidized (right) glutathione in erythrocytes in both groups of patients. 
Orange is group « Tox ≤ 2 » and blue is group « Tox ≥ 3 ». 
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Figure 6.  IL-8 concentration in plasma in both groups of patients. 
Mean value in unirradiated samples is 223.4 pg/mL of plasma.
